Asco 2019 – tepotinib and capmatinib fight over a new lung cancer niche
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
Asco 2019 – the case for Nektar sweetens, slightly
Longer-term data bolster Nektar Therapeutics’ bempegaldesleukin, but things haven’t changed that much since its last disappointment.
Asco 2019 – Seattle sees an Adcetris follow-up on the horizon at last
A mid-stage study of enfortumab illustrates the relevance of nectin-4 in urothelial bladder cancer, and is hailed by experts as registrational.
Asco 2019 – Polo reveals an overall survival hole
The keenly awaited study of Lynparza in pancreatic cancer maintenance fails to show much beyond its headline primary endpoint of progression-free survival.
Asco 2019 – top marks for effort to Merck & Co in gastric cancer
A first-line Keytruda study is nominally positive, but numerous questions remain before approval can be assured.
Asco 2019 – Abstract drop fires the starting gun
Amgen’s KRAS inhibitor, Macrogenics’ breast cancer project and Roche’s entrectinib stand out as the curtain lifts on thousands of abstracts due to be presented at the…
AAN 2019 – Viela Bio takes on Alexion in neuromyelitis optica
The Astrazeneca spinout is plugging data with its rare disease contender inebilizumab, but Alexion’s Soliris is one step ahead.
ISN 2019 – Kidney benefit could help Invokana compete again
Johnson & Johnson’s Invokana has fallen behind SGLT2 rivals over amputation fears, but success in the Credence renal trial, profiled at the International Society of…
EASL 2019 – Research reminds hep B bulls that progress will be slow
Presentations from Assembly Biosciences and Spring Bank Pharmaceuticals could disappoint those hoping to see more definitive steps towards a functional cure for hepatitis…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.